Back to top
more

Pacific Biosciences of California (PACB)

(Real Time Quote from BATS)

$2.45 USD

2.45
7,293,221

+0.01 (0.41%)

Updated Nov 4, 2024 02:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PacBio's (PACB) Q3 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

PacBio (PACB) sees strength in Q3 product revenues, led by robust consumable and instrument sales.

Pacific Biosciences of California (PACB) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -9.52% and 5.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Pacific Biosciences of California (PACB) Q3 Earnings Expected to Decline

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bull of the Day: Mesa Laboratories (MLAB)

by Kevin Cook

Key M&A boosts sales & EPS, opens path to new business with Clinical Genomics Division

PacBio (PACB) Partners with ERGA, Boosts Biodiversity Research

by Zacks Equity Research

PacBio's (PACB) collaboration with ERGA will help scientists to take the first important step toward creating high-quality genetic maps of each plant and animal species in a reliable manner.

PacBio (PACB) Closes Omniome Buyout, Forays Into San Diego

by Zacks Equity Research

PacBio's (PACB) latest acquisition is expected to deliver a differentiated set of products and applications across a wide spectrum of markets.

Pacific Biosciences (PACB) Down 0.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain PacBio (PACB) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about PacBio (PACB) owing to its slew of strategic deals and strength in its Sequel system.

PacBio's (PACB) Q2 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.

Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -5.00% and 0.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Pacific Biosciences of California (PACB) Q2 Earnings Expected to Decline

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PacBio (PACB) Enhances Sequencing Platform Via Latest Buyout

by Zacks Equity Research

PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.

Pacific Biosciences (PACB)-RCIGM Tie Up for Sequencing Research

by Zacks Equity Research

Pacific Biosciences' (PACB) latest research tie-up is likely to use HiFi Sequencing data on some of the most difficult cases of rare pediatric disease and provide insights into the treatment journey.

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH

Pacific Biosciences (PACB) Down 10.8% Despite Narrower Q1 Loss

by Zacks Equity Research

Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.

Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacific Biosciences (PACB) Down 30.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pacific Biosciences' (PACB) Sequel II Gets Deployed by LabCorp

by Zacks Equity Research

Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.

Sweta Killa headshot

5 Stocks That Make Ark Innovation ETF (ARKK) Red Hot

by Sweta Killa

ARKK is centered around the idea of disruptive innovation, which is defined as the introduction of a technologically-enabled new product or service that potentially changes the way the world works.

Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.

Pacific Biosciences of California (PACB) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -102.33% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Pacific Biosciences' (PACB) Q4 Earnings?

by Zacks Equity Research

Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.

Cigna (CI) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Cigna's (CI) fourth-quarter results are likely to reflect strong performance across the business portfolio and lower SG&A costs, partly offset by continued COVID-19 related expenses.

Accuray (ARAY) Releases Encouraging Breast Cancer Study Results

by Zacks Equity Research

Accuray (ARAY) releases positive data from a prospective trial of 338 women with low-risk breast cancer.

Why You Should Retain Pacific Biosciences (PACB) Stock Now

by Zacks Equity Research

Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.